Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
BioSig Technologies Inc is a medical devices business based in the US. BioSig Technologies shares (BSGM) are listed on the NASDAQ and all prices are listed in US Dollars. BioSig Technologies employs 49 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.56|
|52-week range||$2.35 - $5.80|
|50-day moving average||$2.83|
|200-day moving average||$3.42|
|Wall St. target price||$13.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-06)||N/A|
|1 month (2021-09-17)||-10.49%|
|3 months (2021-07-16)||-24.93%|
|6 months (2021-04-16)||-34.02%|
|1 year (2020-10-16)||-54.20%|
|2 years (2019-10-17)||-63.79%|
|3 years (2018-10-17)||4.5|
|5 years (2016-10-17)||66.23%|
|Gross profit TTM||$0|
|Return on assets TTM||-87.84%|
|Return on equity TTM||-160.19%|
|Market capitalisation||$89.4 million|
TTM: trailing 12 months
There are currently 1.8 million BioSig Technologies shares held short by investors – that's known as BioSig Technologies's "short interest". This figure is 1.1% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting BioSig Technologies shares can be evaluated.
BioSig Technologies's "short interest ratio" (SIR) is the quantity of BioSig Technologies shares currently shorted divided by the average quantity of BioSig Technologies shares traded daily (recently around 125555.96455351). BioSig Technologies's SIR currently stands at 14.67. In other words for every 100,000 BioSig Technologies shares traded daily on the market, roughly 14670 shares are currently held short.
However BioSig Technologies's short interest can also be evaluated against the total number of BioSig Technologies shares, or, against the total number of tradable BioSig Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioSig Technologies's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 BioSig Technologies shares in existence, roughly 50 shares are currently held short) or 0.0606% of the tradable shares (for every 100,000 tradable BioSig Technologies shares, roughly 61 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BioSig Technologies.
Find out more about how you can short BioSig Technologies stock.
We're not expecting BioSig Technologies to pay a dividend over the next 12 months.
BioSig Technologies's shares were split on a 2:5 basis on 10 September 2018. So if you had owned 5 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your BioSig Technologies shares – just the quantity. However, indirectly, the new 150% higher share price could have impacted the market appetite for BioSig Technologies shares which in turn could have impacted BioSig Technologies's share price.
Over the last 12 months, BioSig Technologies's shares have ranged in value from as little as $2.35 up to $5.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioSig Technologies's is 1.7339. This would suggest that BioSig Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioSig Technologies, Inc. , together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.